---
title: "Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes"
id: "jama-internal-medicine-24-oral-semaglutide-and-heart-failure-outcomes-in-persons-with-type-2-diabetes"
canonical_url: "https://medichelpline.com/clinical-feed/jama-internal-medicine-24-oral-semaglutide-and-heart-failure-outcomes-in-persons-with-type-2-diabetes"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "JAMA Internal Medicine"
source_url: "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844096"
published_at: "2026-04-01T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/jama-internal-medicine-24-oral-semaglutide-and-heart-failure-outcomes-in-persons-with-type-2-diabetes
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** JAMA Internal Medicine
- **Source URL:** [Original Journal Publication](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844096)
- **Published At:** 2026-04-01T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
This secondary analysis of a randomized clinical trial evaluates the effect of oral semaglutide on heart failure events, major adverse cardiovascular events, and safety among participants with or without heart failure at baseline.
## Clinical Analysis & Structured Key Points
JAMA Internal Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes. Review the original article for the full source wording and details.
## Related Clinical Research

- [Semaglutide Lowers Risk of COVID-19 and Serious Infections in FLOW Trial Participants with T2D and](https://medichelpline.com/clinical-feed/pubmed-41728915.md) (DOI: 10.1093/ndt/gfag036)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes](https://medichelpline.com/clinical-feed/endocrine-news-33-compare-and-contrast-as-glucagon-like-peptide-1-receptor-agonist-access-expands-comparative-heart-outcomes-matter.md)
- [GLP-1 Drugs May Help Reduce Lung Scarring After COVID](https://medichelpline.com/clinical-feed/medical-news-today-0-how-glp-1-drugs-like-ozempic-could-help-prevent-lung-scarring-after-covid.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.